TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells

REFERENCES

• Carballido E, Fishman M. Sipuleucel-T. Prototype for development of anti-tumor vaccines. Curr Oncol Rep. 2011;13:112–119.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314:126–129.
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Harada M, Azuma K, HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2 +cancer patients. Int J Oncol. 2004;24:967– 975.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res. 2004;10:890–896.
   Google Scholar
• Nishimura T, Nakui M, Sato M, The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 2000;46 (Suppl):S52–S61.
   PubMedGoogle Scholar
• Boni A, Muranski P, Cassard L, Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 2008;112:4746–4754.
   PubMed Web of Science ®Google Scholar
• Weynants P, Thonnard J, Marchand M, Delos M, Boon T, Coulie PG. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med. 1999;159:55–62.
   PubMed Web of Science ®Google Scholar
• Alexander RB, Brady F, Leffell MS, Tsai V, Celis E. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology. 1998;51:150–157.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes: implications for understanding the degradative mechanism and antigen presentation. J Biol Chem. 1999;274: 3363–3371.
   PubMed Web of Science ®Google Scholar
• Wieland FT, Gleason ML, Serafini TA, Rothman JE. The rate of bulk flow from the endoplasmic reticulum to the cell surface. Cell. 1987;50:289–300.
   PubMed Web of Science ®Google Scholar
• Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol. 2002;38:1039–1049.
   PubMedGoogle Scholar
• Stevanovic S. Antigen processing is predictable: from genes to T cell epitopes. Transplant Immunol. 2005;14:171–174.
   PubMed Web of Science ®Google Scholar
• Wahl A, Weidanz J, Hildebrand W. Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev Proteomics. 2006;3:641–652.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673–679.
   PubMed Web of Science ®Google Scholar
• Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol. 2006;84: 318–330.
   PubMed Web of Science ®Google Scholar
• Meltzer PS. Gene expression profiling in breast cancer research. Breast Dis. 2004;19:23–27.
   Google Scholar
• Jang JH, Hanash S. Profiling of the cell surface proteome. Proteomics. 2003;3:1947–1954.
   PubMedGoogle Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T, A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer [Journal international du cancer]. 2001;93:243–251.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180:347–352.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol. 2003;170: 4349–4361.
   PubMedGoogle Scholar
• Hickman HD, Luis AD, Bardet W, Cutting edge: class I presentation of host peptides following HIV infection. J Immunol. 2003;171: 22–26.
   PubMed Web of Science ®Google Scholar
• Makler O, Oved K, Netzer N, Wolf D, Reiter Y. Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur J Immunol. 2010;40:1552–1565.
   Google Scholar
• Crowe SR, Turner SJ, Miller SC, Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med. 2003;198:399–410.
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97:4796– 4801.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10: 4688–4698.
   PubMed Web of Science ®Google Scholar
• Hawkins OE, Vangundy RS, Eckerd AM, Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res. 2008;7:1445–1457.
   PubMed Web of Science ®Google Scholar
• Froscher BG, Klinman NR. Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies. J Exp Med. 1986;164:196–210.
   PubMedGoogle Scholar
• Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6:715–726.
   PubMed Web of Science ®Google Scholar
• Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH. Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. J Immunol. 2000;165:5703–5712.
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433–455.
   PubMed Web of Science ®Google Scholar
• Stryhn A, Andersen PS, Pedersen LO, et a. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc Natl. Acad Sci U S A. 1996;93:10338–10342.
   PubMedGoogle Scholar
• Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl. Acad Sci U S A. 1996;93: 1820–1824.
   PubMed Web of Science ®Google Scholar
• Lev A, Denkberg G, Cohen CJ, Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002;62: 3184–3194.
   PubMed Web of Science ®Google Scholar
• Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl. Acad Sci U S A. 2000;97:7969–7974.
   PubMed Web of Science ®Google Scholar
• Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl. Acad Sci U S A. 2002;99:9421–9426.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002;62:5835–5844.
   PubMedGoogle Scholar
• Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol. 2003;170:4349–4361.
   PubMedGoogle Scholar
• Sastry KS, Too CT, Kaur K, Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol. 2011;85:1935–1942.
   PubMed Web of Science ®Google Scholar
• Noy R, Eppel M, Haus-Cohen M, T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. Exp Rev Anticancer Ther. 2005;5:523– 536.
   PubMed Web of Science ®Google Scholar
• Weidanz JA, Nguyen T, Woodburn T, Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 2006;177:5088–5097.
   PubMed Web of Science ®Google Scholar
• Neethling FA, Ramakrishna V, Keler T, Buchli R, Woodburn T, Weidanz JA. Assessing vaccine potency using TCRmimic antibodies. Vaccine. 2008;26:3092–3102.
   Google Scholar
• Kim S, Li L, McMurtrey CP, Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 2010;184:4423–4430.
   PubMed Web of Science ®Google Scholar
• Reiter Y, Di Carlo A, Fugger L, Engberg J, Pastan I. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc Natl. Acad Sci U S A. 1997;94:4631–4636.
   PubMedGoogle Scholar
• Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol. 2003;171: 2197–2207.
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Gallegos M, Denkberg G, Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 2008;68: 6360– 6367.
   PubMed Web of Science ®Google Scholar
• Sergeeva A, Alatrash G, He H, An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011;117: 4262–4272.
   PubMed Web of Science ®Google Scholar
• Verma B, Neethling FA, Caseltine S, TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184: 2156–2165.
   Google Scholar
• Verma B, Jain R, Caseltine S, TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol. 2011;186: 3265–3276.
   PubMed Web of Science ®Google Scholar
• Hawkins O, Verma B, Lightfoot S, An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011;186:6607–6616.
   PubMed Web of Science ®Google Scholar
• Weidanz J, Hildebrand H. Expanding the Targets Available to Therapeutic Antibodies via Novel Disease-Specific Markers. IRI. In Press.
   Google Scholar